HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $34 Price Target
Benzinga Newsdesk 5 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $34 price target.
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $34 price target.